Analysts raise price targets on Rapport Therapeutics after bipolar trial, but stock pullback on discontinuation concerns
Rapport Therapeutics reported a bipolar mania trial that met its primary endpoint with a 3.1‑point placebo‑adjusted YMRS benefit. Raymond James lifted its price target to $86 from $75 and raised the odds of success to 55% from 33%, while H.C. Wainwright increased its target to $66 from $40. Despite the positive readout, the stock’s pre‑market rise peaked at about 84% before retreating, as Wells Fargo warned that higher discontinuation rates could limit upside.
Why it matters
The higher price targets suggest analysts see upside potential, but the noted discontinuation concerns may cap the stock’s rally, creating short‑term volatility for investors.
Key facts
- 1Raymond James raised its price target to $86 from $75. investing.com
- 2Raymond James increased the odds of success for the bipolar program to 55% from 33%. investing.com
- 3The trial showed a 3.1‑point placebo‑adjusted YMRS benefit. investing.com
- 4H.C. Wainwright raised its price target to $66 from $40. finance.yahoo.com
- 5Wells Fargo maintained an Overweight rating with a $51 price target. finance.yahoo.com
- 6RAPP stock rose as high as 84% in pre‑market trading before pulling back. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.